MedTrace Logo

Efficacy and Safety of Jinshuibao for Patients With Chronic Kidney Disease Due to Glomerulonephritis

NCT04349683 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 332

Last updated 2020-04-20

No results posted yet for this study

Summary

This is a multicenter, double-blind randomized controlled study to assess the efficacy and safety of Jinshuibao for patients with CKD due to glomerulonephritis, with a planned follow-up of 48 weeks.

Conditions

Interventions

DRUG

Jinshuibao

6 capsules at a time, 3 times a day (tid).

DRUG

Placebo

6 capsules at a time, 3 times a day (tid).

Sponsors & Collaborators

  • Shanghai 6th People's Hospital

    collaborator OTHER

  • Jemincare

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-04-30
Primary Completion
2021-08-30
Completion
2021-10-30

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04349683 on ClinicalTrials.gov